secwatch.observer — SEC 8-K summary
======================================

Issuer:     Miromatrix Medical Inc. (—)
CIK:        0001527096
Form:       8-K
Filed at:   2023-12-18T23:59:59+00:00
Accession:  0001104659-23-126893
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 2.01, 3.01, 3.03, 5.01, 5.03, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Miromatrix acquisition by United Therapeutics completed; stockholders receive $3.25/sh + CVR
--------------------------------------------------------------------------------

- Tender offer accepted 22,876,102 shares (83.43% outstanding) at $3.25 cash per share plus one CVR.
- Merger effective Dec 13, 2023; Miromatrix becomes wholly owned subsidiary of United Therapeutics.
- CVR entitles holders to up to $1.75 additional cash if mirokidney implanted in human clinical trial by Dec 31, 2025.
- Board of directors replaced; James Edgemond and Paul Mahon appointed, all prior directors resigned.
- Common stock delisted from Nasdaq; company to file Form 15 to suspend SEC reporting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527096/000110465923126893/0001104659-23-126893-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527096/000110465923126893/tm2332683d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-126893

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer